This protocol will allow single agent use of Mylotarg at <_9 mg/m2/dose for AML [or in
combination with all-trans retinoic acid (ATRA) and/or arsenic trioxide for treatment of
APL] and will also allow use of Mylotarg at doses up to 3 mg/m2/dose in combination with anthracycline or nucleoside-antagonist containing treatment regimens. This is an open-label (USA only) expanded access protocol to treat approximately100 patients with relapsed or refractory AML. This protocol will allow the investigator to
choose for each patient enrolled an optimal treatment plan, choosing from several
Mylotarg-containing treatment regimens.